J&J Resumes all Clinical Trial of its COVID-19 Vaccine in the EU

 J&J Resumes all Clinical Trial of its COVID-19 Vaccine in the EU

J&J Resumes all Clinical Trial of its COVID-19 Vaccine in the EU

Shots:

  • J&J has resumed recruitment, enrolment, and vaccination in all studies of its COVID-19 vaccine across the EU, after a temporary pause. Trials in the US, South Africa, and some Latin American countries are already ongoing
  • Clinical trials to be resumed are the P-IIa studies in Germany, the Netherlands, and Spain and P-I/IIa study in Belgium
  • The company is preparing for the initiation of a second P-III study of the COVID-19 vaccine candidate. The trial will evaluate a 2-dose regimen and is anticipated to start later this month across the EU. The study follows positive interim results of the P-I/IIa study, showing the safety profile and immunogenicity of the COVID-19 vaccine was supportive of further development

Click here ­to­ read full press release/ article | Ref: Janssen | Image: Law.com

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post